Attention deficit hyperactivity disorder

BMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7113.894 (Published 11 October 1997) Cite this as: BMJ 1997;315:894

There is no easy answer on whether to medicate or not

  1. Florence Levy, Senior staff specialista
  1. a Prince of Wales Hospital, University of New South Wales, Randwick, New South Wales 2031, Australia

    A syndrome that was described by the ancient Greeks and has been widely observed by physicians since then is likely to have considerable face validity, but there continues to be disagreement about the diagnosis, cause, prevalence, and treatment of attention deficit hyperactivity disorder.1 From the beginning of this century the concept of the condition has evolved from it being a biologically based disorder of behaviour control, from a condition with minimal brain dysfunction, to a disorder characterised by a deficit of attention.2 The main controversy now is about how to treat the condition.

    The past 20 years have seen the development of diagnostic criteria in both Britain and America. In 1981 the criteria of the Diagnostic and Statistical Manual version III (DSM-III) departed from those of the International Classification of Diseases ninth edition (ICD-9) in creating subtypes of attention deficit disorder with and without hyperactivity. Meanwhile, the ICD-9 continued to emphasise “pervasive hyperactivity” as the hallmark of the so called hyperactive syndrome. Now, however, DSM-IV and ICD-10 research criteria for attention deficit hyperactivity disorder and hyperkinetic disorder are almost identical, showing a rapprochement between American and British approaches.

    Theories of aetiology have also evolved, influenced by advances in brain imaging. The current view is that there is dysfunction of prefrontal and subcortical striatal areas of the brain that are implicated in inhibition of irrelevant responses and executive functions.3 Twin studies suggest high heritability of the disorder,4 while a recent molecular genetic study suggests a possible relation with the D4 receptor gene.5 Important questions remain about the relation of the disorder to language and learning disability at the phenotypic and genetic level; and the phenotype may have broadened to include children with learning disability.

    Approaches to treatment have also progressed. An important advance was the use of systematic behaviour modification techniques in the management of disruptive classroom behaviour.6 In America and Australia, however, management has been characterised by an increasing use of stimulant medications such as methylphenidate and dexamphetamine, with 3-5% of primary schoolchildren treated in some American states. Many studies have shown positive effects of stimulant medication in most children diagnosed with attention deficit hyperactivity disorder.7 8 Concerns about addiction have not proved justified, and if the drugs are properly prescribed side effects are not a major concern, although morbidity in terms of appetite, dysphoria, headache, and tics should be carefully monitored.9

    Public concern about overuse of medications has alternated with increasing parental demands for treatment for the disorder. The apparent differences in the use of stimulant drugs between Europe and America have been commented on, but differences of similar magnitude exist within countries, certainly within America and Australia.10 11 Many clinicians in both Britain and America have remained committed to environmental explanations of behaviour and have been loath to use drugs. Additionally, disputes over whether attention deficit hyperactivity disorder is a specific abnormality or merely the extreme end of a range of behaviour have clouded the issue. Nevertheless, when DSM-IV or ICD-10 criteria are used for case selection, significant numbers of the school aged population benefit from careful use of stimulant drugs. Use of these drugs improves not only school performance but often family and social functioning as well.12

    A recent report from Michigan shows that the percentage of boys aged 10-11 years being treated with stimulant drugs was 3-5%, with considerable variation between counties.11 Primary care physicians wrote 84% of prescriptions, while paediatricians wrote 59% of prescriptions for patients younger than 20 years. A similar report from Australia indicates a significant increase in stimulant use between 1988 and 1993, with wide variation between states and territories.10 These data suggest that these paediatricians and primary care physicians have taken a pragmatic approach, tending to fill the void left by their more cautious mental health colleagues. Nevertheless, the widespread use of drugs for this condition by paediatricians, and in some places by general practitioners, raises questions about whether they are adequately aware of, or trained in, behavioural therapies or, indeed, in pharmacotherapy.

    The role of general practitioners should be more clearly defined in screening for attention deficit hyperactivity disorder. The DSM-IV or ICD-10 based screening instruments should be made available for use by general practitioners. In Australia the National Health and Medical Research Council has produced a useful working party report on the condition, which establishes a multidisciplinary policy. The draft report emphasises the use of appropriate rating scales, as well as multiple sources of information including parents, caregivers, professionals, and especially teachers.13

    The promise of advances from genetic and brain imaging methods will require a continued and expanded multidisciplinary effort. Meanwhile, whether to treat the condition with drugs will be determined by the complex interactions of cultural norms, medical manpower, and parental expectations.


    1. 1.
    2. 2.
    3. 3.
    4. 4.
    5. 5.
    6. 6.
    7. 7.
    8. 8.
    9. 9.
    10. 10.
    11. 11.
    12. 12.
    13. 13.
    View Abstract

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial